<DOC>
	<DOCNO>NCT02306902</DOCNO>
	<brief_summary>The study conduct open-label , balance , randomize , two-treatment , two-period , two-sequence , single-dose , crossover , bioequivalence study compare Fenofibrate capsule , USP 130 mg manufacture Ohm Laboratories Inc , NJ 08901 ANTARAÂ® ( fenofibrate ) capsule 130 mg manufacture Ethypharm Industries Saint Cloud , France Oscient Pharmaceuticals Corp. Waltham , MA 02451 healthy , adult , male , human subject feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Fenofibrate Capsules , 130 mg Under Fed Conditions</brief_title>
	<detailed_description>The subject subject breath test alcohol test drug abuse ( opioids cannabinoids ) urine prior admission period . Following overnight fast least 10 hour , high-fat high calorie breakfast serve study subject . Thirty minute start breakfast , single oral dose fenofibrate capsule 130 mg either test reference formulation administer period study , along 240 mL drink water ambient temperature low light condition supervision train study personnel . Blood sample collect pre-dose 1.000 , 2.000 , 3.000 , 4.000 , 4.500 , 5.000 , 5.500 , 6.000 , 6.500 , 7.000 , 7.500 , 8.000 , 8.500 , 9.000 , 9.500 , 10.000 , 11.000 , 12.000 , 16.000 , 24.000 , 36.000 , 48.000 , 72.000 96.000 hour post dose period low light condition . The pre-dose blood sample period collect duplicate ( 2 x 5 mL ) , within period 1.5 hour dosing . Post-dose sample generally collect within 2 minute scheduled time . During course study , safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter , serology urine analysis screening ) . Adverse event monitoring do throughout study . Laboratory parameter hematology biochemistry repeat end study .</detailed_description>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Volunteers meet follow criterion include study Were age range 1845 year . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . Had nonvegetarian dietary habit . Subject history hypersensitivity fenofibrate relate drug drug . Subjects history hepatic severe renal dysfunction , include primary biliary cirrhosis . Subjects history unexplained persistent liver function abnormality . Subjects history preexist gallbladder disease . Subject history myalgia , muscle tenderness weakness myopathy Subject evidence organ dysfunction clinically significant deviation normal physical clinical determination . Clinically abnormal ECG Chest Xray , hematological biochemical parameter was/were outside acceptable limit judge clinically significant investigator . Investigations blood sample subject show presence disease marker HIV 1 2 , Hepatitis B C Viruses syphilis infection . Investigations urine sample subject show clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4 /HPF ) , glucose ( Positive ) Protein ( Positive ) . Subject history serious medical illness include limited gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological hematological disease , diabetes , glaucoma , serious , potentially lifethreatening illness . Inability communicate well ( i.e . language problem , poor mental development , psychiatric illness poor cerebral function ) might impair ability provide , write informed consent . Subject regular smoker , smoke 10 cigarette daily difficulty abstain smoke duration study period . Subject history drug dependence excessive alcohol intake habitual basis difficulty abstain duration study period . Use regular medication ( OTC prescription ) drug metabolize enzyme within 30 day prior Day 1 study . Subject participate clinical trial within 12 week precede admission study ( except subject dropout/withdrawn previous study prior period I dose ) . Subject donate and/or lose 350 mL blood past 3 month , include blood loss study . Consumption alcohol 48 hour prior admission . Consumption grapefruit juice grape fruit supplement contain product 48 hour prior admission . Subject problem ( ) comply study protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>